Afficher la couverture 'PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance | Montaudon, Elodie' en grand format
/5

0 avis

PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance

Archive ouverte

Montaudon, Elodie | Nikitorowicz-Buniak, Joanna | Sourd, Laura | Morisset, Ludivine | Botty, Rania, El | Huguet, Léa | Dahmani, Ahmed | Painsec, Pierre | Némati, Fariba | Vacher, Sophie | Chemlali, Walid | Masliah-Planchon, Julien | Chateau-Joubert, Sophie | Rega, Camilla | Ferreira Leal, Mariana | Simigdala, Nikiana | Pancholi, Sunil | Ribas, Ricardo | Nicolas, André | Meseure, Didier | Vincent-Salomon, Anne | Reyes, Cecile | Rapinat, Audrey | Gentien, David | Larcher, Thibaut | Bohec, Mylène | Baulande, Sylvain | Bernard, Virginie | Decaudin, Didier | Coussy, Florence | Le Romancer, Muriel | Dutertre, Guillaume | Tariq, Zakia | Cottu, Paul | Driouch, Keltouma | Bièche, Ivan | Martin, Lesley-Ann | Marangoni, Elisabetta

Edité par CCSD ; Nature Publishing Group -

International audience. A significant proportion of patients with oestrogen receptor (ER) positive breast cancers (BC) develop resistance to endocrine treatments (ET) and relapse with metastatic disease. Here we perform whole exome sequencing and gene expression analysis of matched primary breast tumours and bone metastasis-derived patient-derived xenografts (PDX). Tran-scriptomic analyses reveal enrichment of the G2/M checkpoint and up-regulation of Polo-like kinase 1 (PLK1) in PDX. PLK1 inhibition results in tumour shrinkage in highly proliferating CCND1-driven PDX, including different RB-positive PDX with acquired palbociclib resistance. Mechanistic studies in endocrine resistant cell lines, suggest an ER-independent function of PLK1 in regulating cell proliferation. Finally, in two independent clinical cohorts of ER positive BC, we find a strong association between high expression of PLK1 and a shorter metastases-free survival and poor response to anastrozole. In conclusion, our findings support clinical development of PLK1 inhibitors in patients with advanced CCND1-driven BC, including patients progressing on palbociclib treatment.

Suggestions

Du même auteur

Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers

Archive ouverte | El-Botty, Rania | CCSD

International audience. Resistance to endocrine treatments and CDK4/6 inhibitors is considered a near-inevitability in most patients with estrogen receptor positive breast cancers (ER + BC). By genomic and metabolom...

A large collection of integrated genomically characterized patient‐derived xenografts highlighting the heterogeneity of triple‐negative breast cancer

Archive ouverte | Coussy, Florence | CCSD

A large collection of integrated genomically characterized patient‐derived xenografts highlighting the heterogeneity of triple‐negative breast cancer

BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers

Archive ouverte | Coussy, Florence | CCSD

Topoisomerase I (TOP1) inhibitors trap TOP1 cleavage complexes resulting in DNA double-strand breaks (DSBs) during replication, which are repaired by homologous recombination (HR). Triple-negative breast cancer (TNBC) could be eli...

Chargement des enrichissements...